Pac Premier
Giving Guide
You are here:  Home  >  Biotech  >  Current Article

Arcutis Biotherapeutics starts eczema drug study

By   /   Wednesday, April 22nd, 2020  /   Comments Off on Arcutis Biotherapeutics starts eczema drug study

    Print       Email
Westlake Village biotech startup Arcutis Biotherapeutics, targeting dermatological diseases, launched a new clinical study of its topical drug to treat chronic hand eczema April 21 with the enrollment of its first patient.  The 12-week Phase 1 study will test safety and tolerability of the product, called ARQ-252, in adult patients with hand eczema. ARQ-252 uses…


    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email